> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 100 Members of Congress Want HHS to Lower Drug Prices
- URL: https://www.fdaweb.com/100-members-of-congress-want-hhs-to-lower-drug-prices/
- Published: 2022-06-29T12:00:00.000Z
- Updated: 2026-09-14T17:50:30.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5152202

Some 100 members of the House and Senate, led by Sen. **Elizabeth Warren** (D-MA) and Rep. **Lloyd Doggett** (D-TX) are calling on HHS secretary **Xavier Becerra** to “swiftly act and use his existing authorities to lower prices on critical prescription drugs.” A [release](https://www.warren.senate.gov/oversight/letters/senators-warren-and-king-and-representatives-doggett-castro-porter-and-jacobs-lead-100-lawmakers-urging-hhs-to-exercise-authority-to-lower-drug-prices-immediately?ref=fdaweb.com) (includes the text of a 6/23 letter) from Warren says the administration has two long-standing statutory authorities to waive patent monopolies and assure reasonable drug prices, including taxpayer protection authority under the Bayh-Dole Act and broad competitive licensing authority under government patent use law codified at 28 USC 1498.

“You can provide immediate relief for millions of patients from Big Pharma’s price gouging and show millions more Americans that you, President Biden, and his administration are on their side,” the lawmakers wrote. The letter says that high medicine prices in the U.S. are the result of prescription drug companies “using their monopoly power to hike prices and pad their bottom lines.” The lawmakers say that using patent licensing authorities under the two laws “could introduce generic or biosimilar competition and dramatic price relief in a matter of months.”